Exhibit



Exhibit 10.3
[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN REDACTED BECAUSE SUCH INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK, “[*]”.



	
																																																														
	FDP Research Subaward Agreement
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	Amendment (Number
	9
	)
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	Pass-Through Entity (PTE)
	Subrecipient
	 

	 
	 
	 
	 
	 
	 

	Yale University
	 
	 
	Entity Name
	Miragen Therapeutics, Inc.
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	gcat5@yale.edu
	 
	Email Address
	jleverone@miragenrx.com
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	[*], MD
	 
	Principal Investigator
	Rusty Montgomery, MD
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	Project Title:
	Mir-29 mimicry as a therapy for pulmonary fibrosis
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	PTE Federal Award No:
	 
	 
	 
	Federal Awarding Agency:
	 
	 

	 
	5UH3HL123886-05 REVISED
	 
	 
	 
	 
	National Institutes of Health (NIH)
	 
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	Subaward Revised  Period  of  Performance:
	Amount Funded This Action:
	 
	 
	Subaward No:
	 

	Start Date:
	September 1, 2018
	End Date:
	Jun 30, 2020
	 
	 
	$ [*]
	 
	 
	 
	GR1004495  (CON-80001453)
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	Total Amount of Federal Funds Obligated to Date:
	 
	 
	 
	Cost Share
	Subject to FFATA:
	Automatic Carryover:
	 

	 
	 
	 
	$ [*]
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	☐
	Yes
	☒
	No
	 
	☒
	Yes
	☐
	No
	 
	☐
	Yes
	☒
	No
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	Amendment(s) to Original Terms and Conditions
This Amendment revises the above-referenced Research Subaward Agreement as follows:
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	•    A detailed budget follows and is hereby incorporated into this amendment as Appendix A.Additional funds in the amount of [*] are hereby authorized as follows:


Direct Costs:  [*]
Indirect Costs: [*]
Total Costs: [*]


	 
	 

	 
	•    If carryover is not automatic (No selected above), the "Total Amount of Federal Funds Obligated to Date" stated above may not reflect the actual balance available. The Subrecipient is responsible for tracking unobligated balances and subsequent carryover approvals from prior budget periods. In the event that funding was not fully expended by the Subrecipient during the prior period, the Subrecipient is not authorized to use funds from any prior periods, unless approval is granted by the PTE.


	 
	 

	 
	•    A detailed budget follows and is hereby incorporated into this amendment as Appendix A.












	 
	 

	 
	 
	 
	 
	

                                For clarity: all amounts stated in this amendment are in United States Dollars.
	 

	 
	 
	 
	 
	 

	All other terms and conditions of this Subaward Agreement remain in full force and effect.
	 

	By an Authorized Official of PTE:
	 
	By an Authorized Official of Subrecipient:
	 

	 
	/s/ Lauren Pite
	 
	 
	April 6, 2020
	 
	 
	/s/ Jason Leverone
	 
	 
	April 7, 2020
	 
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	Name:
	Lauren Pite
	 
	 
	Date
	 
	Name:
	Jason Leverone
	 
	 
	Date
	 
	 

	Title:
	Assoc. Director, Office of Sponsored Projects
	 
	Title:
	CFO
	 




















Program Director/Principal Investigator (Last, First, Middle):
	
			
	DETAILED BUDGET FOR INITIAL BUDGET PERIOD
DIRECT COSTS ONLY
	FROM
9/1/18
	THROUGH
6/30/20




List PERSONNEL (Applicant organization only)
Use Cal, Acad, or Summer to Enter Months Devoted to Project
Enter Dollar Amounts Requested (omit cents) for Salary Requested and Fringe Benefits
	
											
	NAME
	ROLE ON PROJECT
	Cal. Mnths
	Acad. Mnths
	Summer Mnths
	INST.BASE SALARY
	SALARY REQUESTED
	FRINGE BENEFITS
	TOTAL

	Montgomery, Rusty
	PD/PI
	1.21
	 
	 
	[*]
	[*]
	[*]
	[*]

	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 

	SUBTOTALS
	[*]
	[*]
	 

	CONSULTANT COSTS


	 

	EQUIPMENT (Itemize)






	 

	SUPPLIES  (Itemize by category)
Laboratory Supplies: Compound Synthesis: [*], PK Study: [*], Tissue Distribution Study: [*], Dose Range: [*]


	 

	TRAVEL


	 

	INPATIENT CARE COSTS
	 

	OUTPATIENT CARE COSTS
	 

	ALTERATIONS AND RENOVATIONS  (Itemize by category)


	 

	OTHER EXPENSES  (Itemize by category)








	 

	CONSORTIUM/CONTRACTUAL COSTS
	DIRECT COSTS
	 

	SUBTOTAL DIRECT COSTS FOR INITIAL BUDGET PERIOD (Item 7a, Face Page)
	$

	CONSORTIUM/CONTRACTUAL COSTS
	FACILITIES AND ADMINISTRATIVE COSTS
	 

	TOTAL DIRECT COSTS FOR INITIAL BUDGET PERIOD
	$

















Program Director/Principal Investigator (Last, First, Middle):
	
						
	BUDGET FOR ENTIRE PROPOSED PROJECT PERIOD
DIRECT COSTS ONLY

	BUDGET CATEGORY TOTALS
	INITIAL BUDGET PERIOD
(from Form Page 4)
	2nd ADDITIONAL YEAR OF SUPPORT REQUESTED
	3rd ADDITIONAL YEAR OF SUPPORT REQUESTED
	4th ADDITIONAL YEAR OF SUPPORT REQUESTED
	5th ADDITIONAL YEAR OF SUPPORT REQUESTED

	PERSONNEL: Salary and fringe benefits. Applicant organization only.
	 
	 
	 
	 
	 

	CONSULTANT COSTS
	 
	 
	 
	 
	 

	EQUIPMENT
	 
	 
	 
	 
	 

	SUPPLIES
	 
	 
	 
	 
	 

	TRAVEL
	 
	 
	 
	 
	 

	INPATIENT CARE COSTS
	 
	 
	 
	 
	 

	OUTPATIENT CARE COSTS
	 
	 
	 
	 
	 

	ALTERATIONS AND RENOVATIONS
	 
	 
	 
	 
	 

	OTHER EXPENSES
	 
	 
	 
	 
	 

	DIRECT CONSORTIUM/ CONTRACTUAL 
COSTS
	 
	 
	 
	 
	 

	SUBTOTAL DIRECT COSTS
(Sum = Item 8a, Face Page)
	 
	 
	 
	 
	 

	F&A CONSORTIUM/ CONTRACTUAL COSTS
	 
	 
	 
	 
	 

	TOTAL DIRECT COSTS
	 
	 
	 
	 
	 

	TOTAL DIRECT COSTS FOR ENTIRE PROPOSED PROJECT PERIOD
	[*]




JUSTIFICATION. Follow the budget justification instructions exactly. Use continuation pages as  needed.